Can we just put the doctor’s name on the Rx and write “For Office Use”?

That is a common workaround. It is not a national yes, it does not turn a 503A fill into 503B office stock, and commenters in multiple states have said it did not satisfy their board. Educational only — not a cite.

Does USP 795 let our 503A make office stock?

No. USP 795 is how you compound and date a nonsterile preparation. Under 503A, office stock with no patient name is usually not the default path. When a clinic needs unlabeled office stock, the federal path is often a registered 503B under cGMP.

So should we tell the clinic to call a 503B?

Often that is the honest federal answer for true office stock. You can still fill a named-patient Rx if they have a name. Compounding AI Pro is strongest today on 503A-facing USP chapters — confirm 503B / cGMP details with the 503B, licensed text, and counsel.

What if the office wants a controlled substance as stock?

Treat it as another stack, not a labeling tweak. You still need the 503A vs 503B split, plus DEA registration and the clinic’s office-stock ordering path. If you cannot point to those, do not compound.

Can we compound for a doctor’s office with no patient name on the Rx?

“Office use” means sending a compounded preparation to a prescriber’s office for administration or further use with no patient name on the Rx. When a clinic needs office stock without a patient name, the federal path is often a registered 503B outsourcing facility making that stock under current good manufacturing practice (cGMP) — not a regular 503A pharmacy inventing unlabeled stock on the retail bench.

A clinic asking for office stock with no patient name is usually not a 503A yes. Get the federal split straight — 503A fills named-patient Rxs; unlabeled office stock often comes from a 503B — then check your board before you compound.

Start Free Demo

What “office use” means vs a patient-specific Rx

A patient-specific Rx names a person. You compound, you label for that person, you dispense. Office use is the other ask: the clinic wants a compounded preparation on the shelf or in the procedure room — for administration or further use — and there is no patient name on the order.

This page is a federal 503A / 503B / state-board overlay, not a USP 795 table. USP 795 tells you how to compound and date a nonsterile preparation. It does not turn a no-name clinic order into a 503A yes. Educational only. Not legal advice. Not an inspection-outcome guarantee.

Named patient on the Rx → ordinary 503A path. Still confirm labeling and your SOP.
No patient name, clinic wants stock → stop. That is office use, not a blank you fill in later.
Do not treat USP 795 (or 797) as permission to make office stock.

Under 503A, no-patient-name office stock is usually not the default

Federal 503A is the traditional compounding pharmacy. The chapter of the law you live under is built around compounding for an identified patient. A bag or jar with no patient name — sitting at a doctor’s office for whoever walks in — is usually outside that default.

Saying yes on that order from a 503A bench is how a shop walks into a federal problem and a board problem on the same bag. Silence in your state rule is not a federal yes. “We’ve always done it” from the clinic is not a federal yes either.

503A default: named patient, prescription, patient-specific label.
No patient name → do not treat it as a normal 503A fill.
If the clinic later sends a real patient-specific Rx, that is a different order. Fill that path, not the stock ask.

When a clinic needs office stock: the 503B / cGMP path

When the clinic truly needs office stock — a supply on hand, no patient named — the federal path is often a 503B outsourcing facility. That is an FDA-registered plant that can make compounded office stock under current good manufacturing practice (cGMP): the manufacturing quality system used for drug plants — batch records, release testing, stability — not the same as a 503A pharmacy working from USP compounding chapters.

You do not become a 503B by writing “For Office Use” on a 503A label. A regular 503A pharmacy inventing unlabeled stock is not the same thing as buying office stock from a registered 503B. You can still help the clinic: point them to a 503B that makes the item, or fill a true named-patient Rx if they have a name.

Compounding AI Pro’s depth today is strongest on the USP chapters 503A pharmacies live in — verify 503B / cGMP specifics with licensed text, counsel, and the 503B.

503B = registered outsourcing facility making office stock under cGMP.
503A = neighborhood compounding pharmacy filling named-patient Rxs.
A 503A label trick does not convert the order into 503B office stock.

Then the state-board overlay (home state + destination)

After the federal split, read the compounding-standards chapter — not only the general dispensing article. Some boards allow limited 503A office-use in narrow cases. Others treat it as prohibited. Some route leftover office supply through a wholesale / invoice path and may add a sales-percentage cap or a distributor-license trigger.

Your home-state license is not a passport. If you ship to an office in another state, you need that destination state’s nonresident and office-use rules too. A federal 503B answer does not get easier at the state line if you are still shipping from a 503A bench.

Home board compounding-standards chapter first — not only dispensing.
If you ship: destination nonresident + office-use rules second.
State silence is not permission to skip the 503A / 503B federal split.

The “For Office Use” Rx workaround vs wholesale / invoice

A common field workaround is putting the doctor’s name in the patient field and writing “For Office Use” in the directions. That may look complete in your software. It may not satisfy your board, and it does not flip a 503A fill into 503B office stock. Commenters in more than one state have said that label trick did not hold — treat that as culture, not a cite you can take to a hearing.

Some states describe a wholesale / invoice / purchase-order path where the office is the buyer. That path can carry its own license type, invoice records, and sales-percentage or distributor thresholds. It is still not a free pass around 503A’s patient-specific framing. Do not mix an Rx label with a wholesale story after the fact.

Doctor’s name + “For Office Use” is not a national yes.
If your board uses an invoice / PO path, document that path — not a leftover retail Rx.
If you cannot name which path you are on, do not compound yet.

Controlled substances caution

Controls add another stack. Office stock of a scheduled drug is not the same as dispensing a patient-specific controlled Rx. The clinic’s DEA registration and how they are allowed to order office stock can block a path that looked possible for a non-control cream.

Do not paper over a control by putting the prescriber’s name on a retail Rx. If the preparation is scheduled, you need the 503A / 503B split, the board chapter, and the DEA office-stock / ordering path before you say yes.

Identify the schedule before you quote a turnaround time.
Office stock and patient-specific dispensing are different control stories.
When the stacks disagree, the stricter one wins for that order.

What to do on the phone before you say yes

You can answer the clinic without guessing and without stalling on “ask your board.” Walk the stack out loud: 503A is usually patient-specific; unlabeled office stock often comes from a 503B; then you will confirm the board chapter (and the destination state if they want a shipment).

Ask Compounding AI Pro with the actual order language and your state for a cited 503A / USP starting point. Start Free Demo if you are not in the product yet. It does not replace licensed text, counsel, or the 503B’s own quality file.

Named patient? Ordinary 503A fill — confirm SOP and label.
No name, wants stock? Point to a 503B / cGMP source, or wait for a real patient-specific Rx.
If you are still considering a 503A office-use fill: board compounding-standards cite, license / invoice path, and a controls check.
Shipping? Home state plus destination. PIC sign-off when the stack is unclear.

FAQ

Can we just put the doctor’s name on the Rx and write “For Office Use”?: That is a common workaround. It is not a national yes, it does not turn a 503A fill into 503B office stock, and commenters in multiple states have said it did not satisfy their board. Educational only — not a cite.
Does USP 795 let our 503A make office stock?: No. USP 795 is how you compound and date a nonsterile preparation. Under 503A, office stock with no patient name is usually not the default path. When a clinic needs unlabeled office stock, the federal path is often a registered 503B under cGMP.
So should we tell the clinic to call a 503B?: Often that is the honest federal answer for true office stock. You can still fill a named-patient Rx if they have a name. Compounding AI Pro is strongest today on 503A-facing USP chapters — confirm 503B / cGMP details with the 503B, licensed text, and counsel.
What if the office wants a controlled substance as stock?: Treat it as another stack, not a labeling tweak. You still need the 503A vs 503B split, plus DEA registration and the clinic’s office-stock ordering path. If you cannot point to those, do not compound.

Educational information only. Not legal advice. Not an inspection-outcome guarantee. Keep a current USP Compendium subscription. PIC judgment and your board still govern.